"Prices are now so high that despite being prescribed, many Humira patients simply can't afford it," the lawsuit continues. The lawsuit also mentions AbbVie executives' compensation is often tied to the performance of Humira. CEO Richard Gonzalez was paid $19 million in 2022. AbbVie did not respond to a request for comment. The lawsuit was filed in U.S. District Court for the Northern District of Illinois by Edward Camargo, an Indiana resident who began taking Humira at age 19 to treat psoriatic arthritis and psoriasis.